Hypera R&D per Employee
The R&D Spending per Employee of Hypera (HYPE3.SA) as of Oct 11, 2026 is 15,107.87 BRL. In the previous year, R&D Spending per Employee was 16,318.23 BRL — a change of -7.42% (lower).
Get this data via API
Financial Data API
R&D per Employee
15,107.87BRL
YoY
-7.42%
Last updated:
The Hypera R&D per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | R&D per Employee | YoY |
|---|---|---|
| 15,107.87BRL | -7.42% | |
| 16,318.23BRL | -23.31% | |
| 21,278.43BRL | +19.05% | |
| 17,872.95BRL | +25.81% | |
| 14,206.44BRL | -16.46% | |
| 17,005.05BRL | +17.82% | |
| 14,433.39BRL | +74.14% | |
| 8,288.41BRL | -12.39% | |
| 9,460.98BRL | +15.12% | |
| 8,218.10BRL | +548.35% | |
| 1,267.55BRL | -30.03% | |
| 1,811.62BRL | — |
Hypera Stock analysis
Frequently Asked Questions about Hypera stock
R&D Spending per Employee of Hypera is 15,107.87 BRL in 2025.
R&D Spending per Employee of Hypera changed from 16,318.23 BRL to 15,107.87 BRL, representing a -7.42% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of R&D Spending per Employee Hypera since 2006 – with annual values, charts, and detailed analysis.
R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.
R&D Spending per Employee's BRL is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Hypera historically and in real time.
Workforce — Hypera
All Key Metrics — Hypera
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth